VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.543
+0.008 (0.49%)
At close: Jun 25, 2025, 4:00 PM
1.540
-0.002 (-0.16%)
Pre-market: Jun 26, 2025, 8:40 AM EDT

Company Description

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.

It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.

The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.

In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems.

The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.

VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

VivoSim Labs, Inc.
VivoSim Labs logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 13

Contact Details

Address:
11555 Sorrento Valley Road, Suite 100
San Diego, California 92121
United States
Phone 858 224 1000
Website vivosim.ai

Stock Details

Ticker Symbol VIVS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year April - March
Reporting Currency USD
CIK Code 0001497253
ISIN Number US68620A3023

Key Executives

Name Position
Keith E. Murphy Executive Chairman and Corporate Secretary
Norman Staskey President, Chief Financial Officer and Principal Financial Officer
Dr. Curtis M. Tyree Ph.D. Senior Vice President of Strategy and Business Development